Your browser doesn't support javascript.
loading
Oral medical assistance in dying (MAiD): informing practice to enhance utilization in Canada.
Harty, Christopher; Chaput, Alan J; Trouton, Konia; Buna, Donna; Naik, Viren N.
Afiliación
  • Harty C; Department of Anesthesiology and Pain Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
  • Chaput AJ; Department of Anesthesiology and Pain Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
  • Trouton K; University of British Columbia, Vancouver, BC, Canada.
  • Buna D; University of British Columbia, Vancouver, BC, Canada.
  • Naik VN; Department of Anesthesiology and Pain Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada. vnaik@royalcollege.ca.
Can J Anaesth ; 66(9): 1106-1112, 2019 Sep.
Article en En | MEDLINE | ID: mdl-31098962
The legislation Bill C-14 legalized medical assistance in dying (MAiD) in Canada. After thorough assessments of eligibility by two clinicians, Bill C-14 allows for both intravenous-assisted death by a clinician (euthanasia) and prescription of oral medication for self-administration (assisted suicide). Nevertheless, since inception in June 2016, intravenous euthanasia is the main form of delivery of assisted death in Canada. The reasons why oral MAiD is underutilized in Canada are multifactorial. Currently, there is no consensus on either the medications or the protocols for oral administration, nor a comprehensive understanding of the potential side effects and complications associated with different regimens. The quality of evidence for optimal MAiD medications is low, so any suggested recommendations can only be informed by the global but generally anecdotal experience. The challenges for implementing oral MAiD in Canada include a need to enhance clinician comfort in prescribing oral medications as an alternative to intravenous administration. The goals for ideal oral MAiD medications are 100% effectiveness and minimal side effects, while ensuring that the needed dose is both palatable and deliverable in a tolerable oral volume. The Netherlands has the most experience worldwide and barbiturates have emerged as the most common, efficacious, and tolerable agents by patients. Based on this global experience and the over-arching goals for oral MAiD, we recommend the use of a secobarbital suspension combined with antiemetic prophylaxis.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cuidado Terminal / Autoadministración / Eutanasia / Suicidio Asistido Tipo de estudio: Guideline / Prognostic_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Can J Anaesth Asunto de la revista: ANESTESIOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Cuidado Terminal / Autoadministración / Eutanasia / Suicidio Asistido Tipo de estudio: Guideline / Prognostic_studies Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Can J Anaesth Asunto de la revista: ANESTESIOLOGIA Año: 2019 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Estados Unidos